824932-88-9

Basic information

• Product Name: GFT505
• Synonyms: GFT505;elafibranor
• CAS NO: 824932-88-9
• Molecular Formula: C22H24O4S
• Molecular Weight: 384.49
• EINECS: -0
• Mol File: 824932-88-9.mol

Chemical Properties

• Boiling Point: 569.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• Storage Temp.: Amber Vial, -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.34±0.11(Predicted)
• Stability: Light Sensitive
• CAS DataBase Reference: GFT505(CAS DataBase Reference)
• NIST Chemistry Reference: GFT505(824932-88-9)
• EPA Substance Registry System: GFT505(824932-88-9)

Safety Data

• Hazardous Substances Data: 824932-88-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
GFT505 is used as a potential new drug candidate for treating lipid and glucose disorders due to its ability to improve hepatic and peripheral insulin sensitivity in abdominally obese subjects. This makes it a promising option for managing metabolic disorders and related health issues.

Upstream product

• 824932-90-3 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-(tertbutyloxycarbonyldimethylmethyloxy)phenyl]prop-2-en-1-one 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 1778-09-2 4-(Methylthio)acetophenone 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 57-15-8 1,1,1-trichloro-2-methyl-2-propanol 
• 67-66-3 chloroform 
• 67-64-1 acetone 
• 923978-51-2 (E)-2-(2,6-dimethyl-4-(3-(4-(methylsulfonyl)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid 
• 624-92-0 Dimethyldisulphide 
• 639784-17-1 ethyl 2-(4-formyl-2,6-dimethylphenoxy)-2-methylpropanoate 

Relevant articles and documents

POLYMORPHS OF ELAFIBRANOR

The present invention relates to novel crystalline forms of elafibranor.

Preparation method of phenoxyacetic acid derivatives

The invention discloses a preparation method of phenoxyacetic acid derivatives, which adopts a one-step synthesis method and comprises the following steps: reacting (E)-2, 6-dimethyl-4-(3-(4-(methylthio) phenyl)-3-oxopropyl-1-alkene-1-yl) phenol with 2-br

PROCESS FOR PREPARATION OF ELAFIBRANOR

The present invention provides a process for elafibranor, the process comprising reacting compound of formula II or the compound of formula III with a compound of formula IV. The present invention also involve purification of elafibranor by reacting elafi

NOVEL COMPOUNDS AND THEIR USE IN PREPARATION OF ELAFIBRANOR AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF

The present invention relates to the novel compounds of Formula I, and salts thereof and use of said compounds as intermediates for the preparation of (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid (Elafibranor) of Formula II and its pharmaceutical acceptable salts.

DUAL-ACTION ELAFIBRANOR METFORMIN SALT FOR TREATING OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND HYPERTRIGLYCERIDAEMIA

Drugs derived from elafibranor. One or more embodiments relate more particularly to a composition comprising at least one active principle, wherein the at least one active principle comprises an elafibranor metformin salt. One or more embodiments also rel

SOLID FORMS OF ELAFIBRANOR AND PROCESSES THEREOF

The present invention relates to solid forms of Elafibranor, processes for preparation thereof, pharmaceutical salts of Elafibranor, their crystalline and amorphous forms and processes for preparation thereof.

PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATES

The present invention relates to a process for the preparation of elafibranor and novel synthesis intermediates.

GFT505 and preparation method for intermediate thereof

The invention discloses GFT505 and a preparation method for an intermediate thereof. The invention provides the preparation method for an intermediate I of GFT505, comprising the following steps: in an organic solvent, carrying out isomerization reaction

Preparation of 1,3-diphenylprop-2-en-1-one derivatives

The invention relates to a method for the preparation of de 1,3-diphenylprop-2-en-1-one substituted on one of the two phenyl groups by a carboxyalkyloxy group or a carboxyalkylthio group.

Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof

The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.